(Total Views: 705)
Posted On: 07/24/2020 10:11:06 AM
Post# of 148899
Regeneron's preventative anitbody could be valuable. However, it is designed as a preventative agent for those at high risk of contracting Covid (nursing home patients, critical care personnel, etc). It does not treat those infected with covid.
" Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient"
https://investor.regeneron.com/news-releases/...prevention
It is an antibody cocktail, which by its very nature will be short lived.
An effective vaccine will be more likely to induce sustained immunity.
I would be more concerned with treatments that address the immune dysfunction of covid (Humanigen's lenzilumab), that could prove effective.
As has been said recurrently, Leronlimab appears to be in a class by itself. Positive trial results will render these discussions moot.
" Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient"
https://investor.regeneron.com/news-releases/...prevention
It is an antibody cocktail, which by its very nature will be short lived.
An effective vaccine will be more likely to induce sustained immunity.
I would be more concerned with treatments that address the immune dysfunction of covid (Humanigen's lenzilumab), that could prove effective.
As has been said recurrently, Leronlimab appears to be in a class by itself. Positive trial results will render these discussions moot.
(1)
(0)Scroll down for more posts ▼
